Nectin Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nectintx.com
Clinical Trials
1
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials
Phase 1
1 (100.0%)A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Phase 1
Recruiting
- Conditions
- Tumor, SolidMetastatic CancerCancerAdvanced Solid TumorLocally Advanced Solid Tumor
- Interventions
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Nectin Therapeutics Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT05378425
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇺🇸The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
News
No news found